查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1629907

全球预充式註射器市场 - 2025-2033

Global Pre-Filled Syringes Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2023年，全球预充式註射器市场规模达865,606万美元，预估至2033年将达到30,04262万美元，2025-2033年预测期间复合年增长率为15.5%。

预充式註射器是即用型医疗器械，含有预先计量的药物或疫苗剂量。这些注射器预先安装了特定量的药物，方便医疗保健专业人员和患者使用。预充式註射器通常由注射器筒、柱塞和针头或针头护罩组成。有些预充式註射器具有安全功能，例如针头护罩或可伸缩针头，以提高使用和处置过程中的安全性。与某些传统形式的药物包装相比，预充式註射器通常具有更长的保质期，因为它们可以保护药物免受环境因素的影响。

自我照护干预措施的兴起在推动医疗保健市场对预充式註射器的需求方面发挥了重要作用。随着人们在健康管理方面发挥更积极的作用，自我用药变得越来越普遍。例如，根据美国国立卫生研究院 (NIH) 进行的研究，共有 234 名患者完成了问卷调查。有一半（50%）的患者愿意自行用药。然而，只有 37% 的患者更喜欢自行用药，而不是护理师主导的用药。预充式註射器提供了一种使用者友好的解决方案，无需进行复杂的剂量测量，并使个人更容易自行给药。此外，根据哈佛大学的数据，全球每年使用 70 亿支预充式註射器。

市场动态：

驱动程式和限制

自我管理日益普及

自我管理的日益普及极大地推动了预充式註射器市场的成长，预计将在预测期内推动该市场的成长。自我给药允许患者在舒适的家中註射药物，这对于糖尿病、类风湿性关节炎和多发性硬化症等慢性疾病尤其重要。这种便利性减少了频繁去医院的需要，从而为患者和医疗保健提供者节省了时间和成本。

例如，根据美国国立卫生研究院 (NIH) 进行的研究，大多数 (62%) 糖尿病研究患者对自行注射胰岛素持正面态度。儘管177例（72.2%）的研究患者中大多数人自己注射过胰岛素，但只有120例（49.0%）的患者在45度适当注射胰岛素。

根据国际糖尿病联盟估计，到2035年，糖尿病患者将达到5.92亿。糖尿病发生率的上升增加了对自行注射胰岛素的需求，进而增加了对预充式註射器的需求。

家庭医疗保健服务的成长与自我照护趋势密切相关。预充式註射器非常适合家庭医疗保健模式，使患者无需频繁去医院或诊所即可接受必要的治疗。远距医疗和远端监控技术的越来越多的使用支持自我护理干预。可以在虚拟咨询期间开出预装注射器，医疗保健提供者可以远端监控患者的进展，并根据需要提供治疗计划的指导和调整。

此外，根据世界卫生组织估计，世界上五分之一的人口目前生活在人道危机中​​，卫生系统在提供基本服务方面面临挑战。自我保健干预措施是支持个人、家庭和社区在有或没有卫生工作者支持的情况下促进健康、预防疾病、维持健康以及应对疾病和残疾的能力的工具。

药物容量有限

由于限制其实用性的一些挑战，预充式註射器有限的药物容量预计将阻碍市场的成长，特别是对于复杂和大容量的药物。与小瓶和其他包装形式相比，预充式註射器的药物容量通常较小。这限制了他们使用具有特定剂量要求的药物。许多预充式註射器设计用于单剂量应用，通常将总体积限制为 1 至 2 mL。

例如，根据糖尿病期刊组织的资料，胰岛素注射器有不同尺寸，包括 0.3、0.5 和 1.0 mL 尺寸，分别可容纳 30、50 和 100 单位的胰岛素。由于注射器容量的限制，预充式胰岛素注射器的最大剂量限制在 1.0 mL 左右。这对于需要较大剂量的药物来说可能不够。

许多生物製品和高浓度药物需要更大的体积才能有效治疗，但由于容量有限，预充式註射器并不总是合适。对于肿瘤学中使用的药物来说，这项挑战尤其明显，因为需要高浓度和高剂量来维持疗效。例如，市面上大多数预充式註射器的容量最多为 2 mL，这可能不足以容纳单株抗体和高浓度生物製剂等药物。

目录

第一章：市场介绍和范围

  • 报告的目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品分类的片段
  • 按材料分类的片段
  • 设计片段
  • 按应用程式片段
  • 最终使用者的片段
  • 按地区分類的片段

第 3 章：动力学

  • 影响因素
    • 司机
      • 糖尿病盛行率上升
      • 不断进步的技术
    • 限制
      • 资料隐私问题
    • 机会
    • 影响分析

第 4 章：策略洞察与产业展望

  • 市场领导者和先驱
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的知名领导者
    • 拥有成熟产品的市场领导者
  • 新兴新创企业和关键创新者
  • CXO 观点
  • 最新进展和突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：预充式註射器市场，依产品

  • 无针预充式註射器
  • 附针预灌封注射器

第 6 章：预填充注射器市场（依材料）

  • 玻璃预灌封注射器
  • 塑胶预灌封注射器

第 7 章：预充式註射器市场的设计

  • 单室 PFS
  • 双室 PFS

第 8 章：预充式註射器市场（按应用）

  • 糖尿病
  • 类风湿关节炎
  • 眼科
  • 过敏反应
  • 其他的

第 9 章：预填充注射器市场（依最终使用者）

  • 医院和诊所
  • 门诊手术中心
  • 其他的

第 10 章：预填充注射器市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的主要发展
  • 公司基准化分析

第 12 章：公司简介

  • Becton, Dickinson, and Company
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
    • SWOT分析
  • Gerresheimer AG
  • Schott AG
  • Stevanato Group SpA
  • Terumo Corporation
  • Sanofi SA
  • Hikma Pharmaceuticals PLC
  • MedXL Inc.
  • West Pharmaceutical Services, Inc.
  • Cardinal Health

第 13 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 14 章：附录

简介目录
Product Code: MD692

The global pre-filled syringes market reached US$ 8656.06 million in 2023 and is expected to reach US$ 30042.62 million by 2033, growing at a CAGR of 15.5% during the forecast period 2025-2033.

Pre-filled syringes are ready-to-use medical devices containing a pre-measured medication or vaccine dose. These syringes come pre-loaded with a specific amount of a drug, making them convenient for healthcare professionals and patients. The pre-filled syringe typically consists of a syringe barrel, a plunger, and a needle or a needle shield. Some pre-filled syringes come with safety features, such as needle shields or retractable needles, to enhance safety during use and disposal. Pre-filled syringes often have a longer shelf life compared to some traditional forms of medication packaging, as they can protect the drug from environmental factors.

The rise of self-care interventions has played a significant role in driving the demand for pre-filled syringes in the healthcare market. Self-administration of medications is becoming increasingly common as people take a more active role in managing their health. For instance, according to the Study conducted by the National Institute of Health (NIH), in total, 234 patients completed the questionnaire. Half (50%) of the patients were willing to self-administer medication. However, only 37% of patients preferred self-administration of medication over nurse-led medication administration. Pre-filled syringes offer a user-friendly solution, eliminating the need for complex dosage measurements and making it easier for individuals to self-administer their medications. Additionally, according to Harvard University, 7 billion prefilled syringes are used annually around the world.

Market Dynamics: Drivers & Restraints

Rising popularity of self-administration

The rising popularity of self-administration is significantly driving the growth of the pre-filled syringes market and is expected to drive the market over the forecast period. Self-administration allows patients to inject medications in the comfort of their homes, which is particularly important for chronic conditions such as diabetes, rheumatoid arthritis and multiple sclerosis. This convenience reduces the need for frequent hospital visits, thus saving time and costs for both patients and healthcare providers.

For instance, according to the study conducted by the National Institute of Health (NIH), the majority (62%) of the diabetes study patients had a favorable attitude toward insulin self-administration. Although the majority of 177(72.2%) of the study patients have administered insulin themselves, only 120(49.0%) of the patients injected insulin appropriately at 45 degrees.

According to the International Diabetes Federation estimated that diabetes reach 592 million in the year 2035. Similarly, there were more than 1.8 million diabetes patients in Ethiopia with a national prevalence of 4.36% among the adult population. This rising diabetes increases the demand for insulin self-administration, which in turn increases the demand for prefilled syringes.

The growth of home healthcare services is closely tied to the self-care trend. Pre-filled syringes fit well within the home healthcare model, allowing patients to receive necessary treatments without the need for frequent hospital or clinic visits. The increasing use of telemedicine and remote monitoring technologies supports self-care interventions. Pre-filled syringes can be prescribed during virtual consultations, and healthcare providers can remotely monitor patients' progress, offering guidance and adjustments to treatment plans as needed.

Additionally, according to WHO, estimated that 1 in 5 of the world's population are now living in humanitarian crises, in which health systems are challenged to deliver essential services. Self-care interventions are tools that support the ability of individuals, families and communities to promote health, prevent disease, maintain health, and cope with illness and disability with or without the support of a health worker.

Limited drug capacity

The limited drug capacity of pre-filled syringes is expected to hamper the growth of the market due to several challenges that restrict their utility, especially for complex and large-volume drugs. Pre-filled syringes typically have a smaller drug capacity compared to vials and other packaging formats. This restricts their use of medications with specific dosage requirements. Many pre-filled syringes are designed for single-dose applications, often limiting the total volume to 1 to 2 mL.

For instance, according to the Diabetes Journals Organization, insulin syringes come in different sizes, including 0.3, 0.5 and 1.0 mL sizes that hold up to 30, 50, and 100 units of insulin, respectively. Insulin pre-filled syringes are limited to a maximum dose of around 1.0 mL due to syringe capacity constraints. This may not be sufficient for medications requiring larger doses.

Many biologics and high-concentration drugs require larger volumes for effective treatment, but pre-filled syringes are not always suitable due to limited capacity. The challenge is particularly pronounced with drugs used in oncology, where high concentrations and volumes are needed to maintain efficacy. For instance, the majority of pre-filled syringes on the market can hold up to 2 mL, which might not be sufficient for drugs like monoclonal antibodies and high-concentration biologics.

Segment Analysis

The global pre-filled syringes market is segmented based on product, material, design, application, end-user and region.

Product Type:

The needled prefilled syringes segment is expected to dominate the pre-filled syringes market share

Needled pre-filled syringes are widely used for a range of applications, including insulin administration, vaccines and biologic therapies. Insulin and diabetes management are prime examples, where pre-filled syringes equipped with needles provide a reliable and convenient method for daily self-administration. Needled pre-filled syringes are preferred for their ability to deliver drugs directly into the bloodstream, ensuring effective therapeutic outcomes. The presence of a needle allows for precise dosing, which is crucial for biologics and therapies requiring targeted delivery.

For instance, in September 2024, BD (Becton, Dickinson and Company) released the BD Neopak XtraFlow Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak Glass Prefillable Syringe platform to serve the growing market for biologic therapies. This solution features an 8-millimeter needle length and thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles by reducing the injection force and time required for a fixed solution viscosity. The BD Neopak Glass Prefillable Syringe platform is designed to address key development needs for biologic drugs.

Advanced safety mechanisms integrated into needled pre-filled syringes improve their safety profile. These features have become essential in healthcare settings, especially for hospital administrations, and for patient safety. For instance, in August 2024, Schreiner MediPharm introduced Needle-Trap Secu, a protection label with a newly integrated seal function that enhances sustainability and cost efficiency in the storage, transportation and disposal of prefilled syringes. Its compact design technology effectively protects against needlestick injuries while saving space and resources.

Geographical Analysis

North America is expected to hold a significant position in the pre-filled syringes market share

There is a growing trend towards self-administration in North America especially in the United States, driven by the convenience it offers to patients and caregivers. Self-injection pens and needled pre-filled syringes are widely used for managing chronic conditions like diabetes, rheumatoid arthritis, and multiple sclerosis. For instance, the National Institute of Health reports indicate that in the United States, approximately 40% of the population self-medicates, this further boosts the demand for prefilled syringes in the region.

North America is a major market for biologics and biosimilars, which are primarily delivered using pre-filled syringes. The growing prevalence of chronic diseases and the increasing adoption of biologics for treatment have driven the demand for pre-filled syringes in the region. For instance, according to the Pharmaceutical Research and Manufacturers of America, as of the end of 2022, 40 biosimilars have been approved and there are 27 biosimilars on the market in the U.S. competing against ten brand biologics with several more scheduled to launch throughout 2023.

Asia-Pacific is growing at the fastest pace in the Pre-Filled Syringes market

Rapidly improving healthcare infrastructure across countries like China, India, Japan, South Korea, and others in the APAC region is driving the adoption of advanced medical devices like pre-filled syringes. Investments in healthcare facilities, government initiatives to improve access to quality healthcare, and the establishment of specialized hospitals and clinics are boosting the demand for pre-filled syringes. For instance, in China, the government's healthcare reforms have led to increased spending on healthcare infrastructure, which is accelerating the adoption of advanced drug delivery systems such as pre-filled syringes.

For instance, in June 2022, WuXi Biologics launched the GMP operation of its new drug product facility DP5 located in Wuxi, China. The DP5 is the ninth operational drug product facility in the global network of WuXi Biologics. The DP5 facility features an isolator filling line for continuous and steady filling services, which offers multiple volume delivery options for pre-filled syringes (PFS), including 1 mL Long, 1 mL, 2.25 mL and 3 mL, notes WuXi. The maximum filling speed reportedly can reach 400 PFS/min to support 17 million syringes of drug products manufacturing every year.

The rising prevalence of chronic diseases such as diabetes, cardiovascular diseases and cancer in the APAC region is a major driver. These diseases often require long-term treatment regimens, making pre-filled syringes a convenient and preferred method of drug delivery. For instance, China has one of the highest numbers of diabetes patients, currently having 140.9 million people with diabetes, which is set to increase to 174.4 million by 2045., driving the demand for insulin-pre-filled syringes

Competitive Landscape

The major global players in the pre-filled syringes market include Becton, Dickinson, and Company, Gerresheimer AG, Schott AG, Stevanato Group S.p.A., Terumo Corporation, Sanofi S.A., Hikma Pharmaceuticals PLC, MedXL Inc., West Pharmaceutical Services, Inc., Cardinal Health and among others.

Key Developments

  • In September 2024, BD (Becton, Dickinson and Company) announced the commercial release of the BD Neopak XtraFlow Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak Glass Prefillable Syringe platform to serve the growing market for biologic therapies.
  • In March 2024, Biocon Biologics, a subsidiary of Biocon, on Monday officially announced a settlement with Bayer and Regeneron Pharmaceuticals. This agreement allows Biocon Biologics to launch Yesafili, a proposed biosimilar to EYLEA (aflibercept) Injection, in the Canadian market. Under the terms of the company agreement, Biocon Biologics has secured a launch date for Yesafili 2 mg New Drug Submission (NDS) for vials and prefilled syringes, with the launch set up to July 1, 2025.
  • In January 2023, Schreiner MediPharm presented a security label for syringes at Pharmapack Paris in early February. Met with ample interest among eventgoers, the company's Syringe-Closure-Wrap is a multifunctional label for pre-filled syringes that provides a clear first-opening indication, enabling the detection of previous use, tampering or counterfeiting attempts.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global pre-filled syringes market report delivers a detailed analysis with 78 key tables, more than 71 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product
  • 2.4. Snippet by Material
  • 2.5. Snippet by Design
  • 2.6. Snippet by Application
  • 2.7. Snippet by End-User
  • 2.8. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Diabetes
      • 3.1.1.2. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Data Privacy Concerns
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Pre-Filled Syringes Market, By Product

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 5.1.2. Market Attractiveness Index, By Product
  • 5.2. Needle Free Prefilled Syringes*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Needled Prefilled Syringes

6. Pre-Filled Syringes Market, By Material

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 6.1.2. Market Attractiveness Index, By Material
  • 6.2. Glass Prefilled Syringes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Plastic Prefilled Syringes

7. Pre-Filled Syringes Market, By Design

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 7.1.2. Market Attractiveness Index, By Design
  • 7.2. Single Chambered PFS*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Dual Chambered PFS

8. Pre-Filled Syringes Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Diabetes*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Rheumatoid Arthritis
  • 8.4. Ophthalmology
  • 8.5. Anaphylaxis
  • 8.6. Others

9. Pre-Filled Syringes Market, By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals & Clinics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Others

10. Pre-Filled Syringes Market, By Regional Market Analysis and Growth Opportunities

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.8.1. U.S.
      • 10.2.8.2. Canada
      • 10.2.8.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.8.1. Germany
      • 10.3.8.2. U.K.
      • 10.3.8.3. France
      • 10.3.8.4. Spain
      • 10.3.8.5. Italy
      • 10.3.8.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.8.1. Brazil
      • 10.4.8.2. Argentina
      • 10.4.8.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.8.1. China
      • 10.5.8.2. India
      • 10.5.8.3. Japan
      • 10.5.8.4. South Korea
      • 10.5.8.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape and Market Positioning

  • 11.1. Competitive Overview and Key Market Players
  • 11.2. Market Share Analysis and Positioning Matrix
  • 11.3. Strategic Partnerships, Mergers & Acquisitions
  • 11.4. Key Developments in Product Portfolios and Innovations
  • 11.5. Company Benchmarking

12. Company Profiles

  • 12.1. Becton, Dickinson, and Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
    • 12.1.5. SWOT Analysis
  • 12.2. Gerresheimer AG
  • 12.3. Schott AG
  • 12.4. Stevanato Group S.p.A.
  • 12.5. Terumo Corporation
  • 12.6. Sanofi S.A.
  • 12.7. Hikma Pharmaceuticals PLC
  • 12.8. MedXL Inc.
  • 12.9. West Pharmaceutical Services, Inc.
  • 12.10. Cardinal Health

LIST NOT EXHAUSTIVE

13. Assumption and Research Methodology

  • 13.1. Data Collection Methods
  • 13.2. Data Triangulation
  • 13.3. Forecasting Techniques
  • 13.4. Data Verification and Validation

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us